-
Je něco špatně v tomto záznamu ?
An anticancer Os(II) bathophenanthroline complex as a human breast cancer stem cell-selective, mammosphere potent agent that kills cells by necroptosis
V. Novohradsky, L. Markova, H. Kostrhunova, Z. Trávníček, V. Brabec, J. Kasparkova,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
Nature Open Access
od 2011-12-01
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Health & Medicine (ProQuest)
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
Springer Nature OA/Free Journals
od 2011-12-01
- MeSH
- apoptóza účinky léků MeSH
- chloracetáty farmakologie MeSH
- cymeny farmakologie MeSH
- fenantroliny farmakologie MeSH
- komplexní sloučeniny farmakologie MeSH
- lidé MeSH
- lokální recidiva nádoru patologie MeSH
- nádorové buněčné linie MeSH
- nádorové kmenové buňky účinky léků metabolismus MeSH
- nádorové mikroprostředí účinky léků MeSH
- nádory prsu farmakoterapie patologie MeSH
- nekroptóza účinky léků MeSH
- nekróza metabolismus MeSH
- organoplatinové sloučeniny farmakologie MeSH
- osmium farmakologie MeSH
- proliferace buněk účinky léků MeSH
- protinádorové látky farmakologie MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Conventional chemotherapy is mostly effective in the treatment of rapidly-dividing differentiated tumor cells but has limited application toward eliminating cancer stem cell (CSC) population. The presence of a very small number of CSCs may contribute to the development of therapeutic resistance, metastases, and relapse. Thus, treatment failure by developing novel anticancer drugs capable of effective targeting of CSCs is at present a major challenge for research focused on chemotherapy of cancer. Here, we show that Os(II) complex 2 [Os(η6-pcym)(bphen)(dca)]PF6 (pcym = p-cymene, bphen = bathophenanthroline, and dca = dichloroacetate), is capable of efficient and selective killing CSCs in heterogeneous populations of human breast cancer cells MCF-7 and SKBR-3. Notably, its remarkable submicromolar potency to kill CSCs is considerably higher than that of its Ru analog, [Ru(η6-pcym)(bphen)(dca)]PF6 (complex 1) and salinomycin, one of the most selective CSC-targeting compounds hitherto identified. Furthermore, Os(II) complex 2 reduces the formation, size, and viability of three-dimensional mammospheres which more closely reflect the tumor microenvironment than cells in traditional two-dimensional cultures. The antiproliferation studies and propidium iodide staining using flow cytometry suggest that Os(II) complex 2 induces human breast cancer stem cell death predominantly by necroptosis, a programmed form of necrosis. The results of this study demonstrate the promise of Os(II) complex 2 in treating human breast tumors. They also represent the foundation for further preclinical and clinical studies and applications of Os(II) complex 2 to comply with the emergent need for human breast CSCs-specific chemotherapeutics capable to treat chemotherapy-resistant and relapsed human breast tumors.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028816
- 003
- CZ-PrNML
- 005
- 20210114155206.0
- 007
- ta
- 008
- 210105s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-019-49774-x $2 doi
- 035 __
- $a (PubMed)31527683
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Novohradsky, Vojtech $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 612 65, Brno, Czech Republic.
- 245 13
- $a An anticancer Os(II) bathophenanthroline complex as a human breast cancer stem cell-selective, mammosphere potent agent that kills cells by necroptosis / $c V. Novohradsky, L. Markova, H. Kostrhunova, Z. Trávníček, V. Brabec, J. Kasparkova,
- 520 9_
- $a Conventional chemotherapy is mostly effective in the treatment of rapidly-dividing differentiated tumor cells but has limited application toward eliminating cancer stem cell (CSC) population. The presence of a very small number of CSCs may contribute to the development of therapeutic resistance, metastases, and relapse. Thus, treatment failure by developing novel anticancer drugs capable of effective targeting of CSCs is at present a major challenge for research focused on chemotherapy of cancer. Here, we show that Os(II) complex 2 [Os(η6-pcym)(bphen)(dca)]PF6 (pcym = p-cymene, bphen = bathophenanthroline, and dca = dichloroacetate), is capable of efficient and selective killing CSCs in heterogeneous populations of human breast cancer cells MCF-7 and SKBR-3. Notably, its remarkable submicromolar potency to kill CSCs is considerably higher than that of its Ru analog, [Ru(η6-pcym)(bphen)(dca)]PF6 (complex 1) and salinomycin, one of the most selective CSC-targeting compounds hitherto identified. Furthermore, Os(II) complex 2 reduces the formation, size, and viability of three-dimensional mammospheres which more closely reflect the tumor microenvironment than cells in traditional two-dimensional cultures. The antiproliferation studies and propidium iodide staining using flow cytometry suggest that Os(II) complex 2 induces human breast cancer stem cell death predominantly by necroptosis, a programmed form of necrosis. The results of this study demonstrate the promise of Os(II) complex 2 in treating human breast tumors. They also represent the foundation for further preclinical and clinical studies and applications of Os(II) complex 2 to comply with the emergent need for human breast CSCs-specific chemotherapeutics capable to treat chemotherapy-resistant and relapsed human breast tumors.
- 650 _2
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a apoptóza $x účinky léků $7 D017209
- 650 _2
- $a nádory prsu $x farmakoterapie $x patologie $7 D001943
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a chloracetáty $x farmakologie $7 D062845
- 650 _2
- $a komplexní sloučeniny $x farmakologie $7 D056831
- 650 _2
- $a cymeny $x farmakologie $7 D000081007
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nekroptóza $x účinky léků $7 D000079302
- 650 _2
- $a nekróza $x metabolismus $7 D009336
- 650 _2
- $a lokální recidiva nádoru $x patologie $7 D009364
- 650 _2
- $a nádorové kmenové buňky $x účinky léků $x metabolismus $7 D014411
- 650 _2
- $a organoplatinové sloučeniny $x farmakologie $7 D009944
- 650 _2
- $a osmium $x farmakologie $7 D009992
- 650 _2
- $a fenantroliny $x farmakologie $7 D010618
- 650 _2
- $a nádorové mikroprostředí $x účinky léků $7 D059016
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Markova, Lenka $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 612 65, Brno, Czech Republic.
- 700 1_
- $a Kostrhunova, Hana $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 612 65, Brno, Czech Republic.
- 700 1_
- $a Trávníček, Zdeněk $u Division of Biologically Active Complexes and Molecular Magnets, Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University, Slechtitelu 27, 783 71, Olomouc, Czech Republic.
- 700 1_
- $a Brabec, Viktor $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 612 65, Brno, Czech Republic. Department of Biophysics, Faculty of Science, Palacky University, Slechtitelu 27, 783 71, Olomouc, Czech Republic.
- 700 1_
- $a Kasparkova, Jana $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, 612 65, Brno, Czech Republic. jana@ibp.cz.
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 9, č. 1 (2019), s. 13327
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31527683 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114155204 $b ABA008
- 999 __
- $a ok $b bmc $g 1609151 $s 1119996
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 9 $c 1 $d 13327 $e 20190916 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- LZP __
- $a Pubmed-20210105